Las proteínas antiapoptóticas Bcl2 y BclX no protegen a las células de leucemia mieloide crónica de la parada proliferativa inducida por imatinib by Gómez Casares, María Teresa et al.
27
Antiapoptotic proteins Bcl2 and BclX do not
protect chronic myeloid leukemia cells from
imatinib-mediated growth arrest
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ABSTRACT
Imatinib (Glivec, Gleevec, STI571), a Bcr-Abl kinase inhibitor, is the most used
drug in chronic myeloid leukemia. Imatinib induces apoptosis in a number of
CML-derived cell lines, including K562. However, in order to achieve hematological
remissions it is required chronic treatment with the drug, a fact inconsistent with
a cytotoxic mechanism of imatinib in vivo. In this work we have analysed the
effects of imatinib on the proliferation and apoptosis of K562-derived cell lines
with constitutive expression of the anti-apoptotic genes Bcl2 and BclX. We found
that imatinib-mediated apoptosis was completely abrogated in both Bcl2- and BclX-
cell lines. However, imatinib inhibited proliferation, although growth rate was
higher than in parental K562. We conclude that, besides its apoptotic effect,
imatinib acts through an apoptosis-independent mechanism to arrest cell growth.
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RESUMEN
Las proteínas antiapoptóticas Bcl2 y BclX no protegen a las células de
leucemia mieloide crónica de la parada proliferativa inducida por imatinib
El imatinib (Glivec, Gleevec, STI571) es un inhibidor de la quinasa Bcr-Abl, y
es el fármaco de más uso en leucemia mieloide crónica (LMC). El imatinib induce
apoptosis en varias líneas celulares derivadas de LMC, entre ellas K562. Sin embar-
go, para obtener remisión hematológica es necesario el tratamiento continuado
con imatinib, un hecho no consistente con un mecanismo de acción citotóxico in
vivo del fármaco in vivo. En este trabajo hemos analizado un los efectos del ima-
tinib en la proliferación y apoptosis de líneas celulares derivadas de K562 con
expresión constitutiva de las proteínas antiapoptóticas Bcl2 y BclX. Hemos encon-
trado que la apoptosis mediada por imatinib era completamente abolida en las
líneas celulares con expresión de Bcl2 y BclX. Sin embargo, el imatinib inhibía la
proliferación, aunque este efecto fue menos severo que en las células parentales
K562. Concluimos que, además de su efecto apoptótico, el imatinib actúa a través
de un mecanismo independiente de la apoptosis para detener la proliferación.
Palabras clave: Bcl2.—BclX.—Imatinib.—K562.—CML.
INTRODUCTION
Bcl2 and BclX (BclXL) are proteins of the BH2 super family. Both
are mitochondria-located proteins with an apoptosis inhibitory
activity. Most follicular lymphoma carry a chromosomal translocation
involving Bcl2 locus that results in Bcl2 deregulation, and there are
consistent reports of Bcl2 and BclX overexpression in many types of
human cancer, through mechanisms different from chromosome
translocation (1). Leukemia, including CML, is frequently associated
to Bcl2 and BclX overexpression (2, 3). Impaired apoptosis is
considered a crucial step in tumorigenesis. Indeed, a defective cell
death program endows neoplastic cells with selective advantages, and
with resistance to cytotoxic therapy.
Most of the patients of chronic myeloid leukemia (CML) are
diagnosed in chronic phase, characterized by the clonal expansion of
myeloid precursors, followed by a blastic crisis phase. The molecular
hallmark of CML is the Bcr-Abl kinase, expressed in more than 95%
of CML. This is a fusion protein with constitutive tyrosine kinase
activity formed on the Philadelphia chromosome, that arises from a
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reciprocal translocation between chromosomes 9 and 22 (4). Bcr-Abl
is believed to be the major responsible for CML pathogenesis as it is
able to transform hematopoietic cells and to induce myeloproliferative
disease in mice after bone marrow repopulation with Bcr-Abl-
expressing cells. The transformation pathways induced by Bcr-Abl are
not fully understood, but it seems clear that apoptosis protection is a
major mechanism by which Bcr-Abl allows the expansion of the
leukemic clon (5, 6).
Although the outcome of CML in blast crisis is fatal, the disease
can be cured by allogenic bone marrow transplantation during
chronic phase. Interferon-a (IFNa) has been used in CML treatment,
and in those patients where IFNa treatment failed, the treatment was
based on hydroxyurea or busulfan (7). More recently, a new drug,
imatinib (formerly STI571, trade name «Gleevec», or «Glivec»), was
introduced in CML treatment. Imatinib is a potent inhibitor of the
tyrosine kinase activity of Bcr-Abl and it is rapidly displacing other
treatments for CML (8). Imatinib is active in vitro on CML-derived
cells, and it has been proposed that imatinib mechanism of action
involves the apoptosis that follows Bcr-Abl inhibition (5, 6, 8).
In the present work we study the effect of Bcl2 and BclX
overexpression on the response to imatinib of a CML-derived cell line.
Our data indicate that both proteins inhibit the imatinib-mediated
apoptosis but imatinib still impairs cell growth. Thus, imatinib acts
through apoptosis-dependent and apoptosis-independent pathways.
The results suggests that the action of imatinib as anti-CML drug in
vivo may depend more on its cytostatic effects than on its apoptotic
effects.
MATERIAL AND METHODS
Cell culture and drugs
K562 cell line was obtained from the American Type Culture
Collection. Kbcl2v cells are K562 infected with a Bcl-2 retrovirus and
expressing high levels of Bcl-2 protein. K562-BclXL (KbclX) are cells
transfected with Bcl-XL (9). All cell lines were grown in RPMI 1640
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medium (Invitrogen) containing 8% fetal calf serum and gentamycin
(80 mg/mL). For proliferation assays, exponentially growing cells
at a concentration of 250,000 cells per mL were treated with the
indicated concentrations of hydroxyurea (Sigma), IFNα (kindly
provided by Roche Farma, Madrid, Spain), busulfan (Sigma) and
imatinib (kindly provided by Novartis, Basel, Switzerland).
Cell proliferation and apoptosis assays
Cells were counted in a hemocytometer. When appropriate, cell
viability was scored with trypan blue vital staining. For thymidine
incorporation assays, cells were incubated with 1 μCi/mL of 3H-
thymidine for 2 h, harvested onto glass wool filters and the
radioactivity was counted by liquid scintillation. Each experiment was
repeated at least three times. Cells with apoptotic morphology were
analyzed by May-Grünwald-Giemsa staining of cytocentrifuge
preparations, and scored by light microscopy. Binding of annexin V
to cell surface was carried out by flow cytometry with annexin V-FITC
following the manufacturer’s instructions (Genzyme Diagnostics).
Northern analysis
RNAs were prepared by the guanidine thiocyanate method. RNAs
(15 μg of total RNA per lane) were separated by electrophoresis
through agarose-formaldehyde gel and transferred to nitrocellulose.
Probe labeling with [α-32P]dCTP and filter hybridization were carried
out according to standard procedures. Probe for human BCL2 was a
1.8 kb fragment from human cDNA.
RESULTS AND DISCUSSION
In order to investigate a possible effect of Bcl2 and BclX on the
antiproliferative activity of imatinib , we compared the growth rates
of K562 (parental cells), Kbcl2v and KbclX cells in response to
imatinib at two concentrations of the drug (0.5 µM and 2.5 µM).
The results are shown in Fig. 1A, and demonstrate that imatinib
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significantly inhibited the growth of Kbcl2v and KbclX cells, athough
to a lesser extent than K562.
It was conceivable that imatinib impaired the expression of the
ectopic Bcl2 or BclX genes. To test this possibility we analysed the
Bcl2 mRNA in Kbcl2v cells treated with imatinib. The results (Fig.
1B) showed that imatinib did not affect Bcl2 expression at
concentrations that were effective on the growth of Kbcl2v cells. As
previously described, parental K562 do not express Bcl-2 (9).
FIGURE 1. Effect of imatinib on K562 expressing Bcl-2 and Bcl-XL. (A) Inhibition of
proliferation determined by DNA synthesis in K562, Kbcl2v and KbclX treated for
the indicated period of times with 0.5 µM and 2.5 µM imatinib. (B) BCL2 expression
in K562 and Kbcl2v cells treated for 1, 2 or 3 days with 0.5 μM imatinib, as analyzed by
Northern blot analysis. A picture of the filter after transfer showing the rRNAs
stained with ethidium bromide is shown to assess the loading and integrity of the RNAs.
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The retardation in growth rate of Kbcl2v and KbclX provoked
by imatinib could be explained by reduced cell proliferation or
by increased apoptosis. To investigate this point we determined the
DNA synthesis rate of DNA by the 3H-thymidine incorporation
method in the three cell lines treated with 0.5 µM and 2.5 µM
imatinib for 48 and 72 h. The results indicate that DNA synthesis
in parental K562 (as well as cells transfected with the empty vector,
KXLSN, not shown) was almost completely suppressed after 72 h
of treatment with 0.5 and 2.5 µM imatinib. Imatinib also decreased
the DNA synthesis in Kbcl2v and KbclX in a time- and dose-
dependent manner (Fig. 2A). However, DNA synthesis rate in Kbcl2v
and KbclX was not suppressed but dramatically reduced (20% and
30% respectively with respect to controls). These differences in DNA
synthesis were roughly consistent with the growth curves of the
distinct cell lines (Fig. 1A).
Next we compared the effect of imatinib with the other three
drugs used in CML treatment (hydroxyurea, busulfan and IFNα). We
chose drug concentrations slightly above the minimal cytostatic
concentrations for the three cell lines: 2000 UI of IFNα per mL, 0.5
mM hydroxyurea and 0.5 mM busulfan (data not shown). K562,
Kbcl2v and KbclX cells were treated with the drugs at the indicated
concentrations for 48 h and the 3H-thymidine incorporation was
measured. The results (Fig. 2B) indicate that neither Bcl-2 nor Bcl-
XL conferred resistance to the antiproliferative effect of busulfan,
IFNα and hydroxyurea in K562, in accordance with the absence of
cells showing apoptotic morphology (not shown).
Next we analysed whether Bcl2v and BclX were capable to
antagonize the apoptosis elicited by imatinib in K562. We measured
the apoptosis extent by determining the binding of annexin V to cell
surfaces. This protein binds to phosphatidyl serine, which is exposed
to the outer layer of plasma membrane during apoptosis. K562,
Kbcl2v and KbclX cells were treated with annexin V-FITC and
binding determined by flow cytometry. The results (Fig. 3A) indicate
that imatinib-mediated apoptosis was dramatically reduced in Kbcl2v
and KbclX. Similar result was observed by scoring cells with
apoptotic morphology after Giemsa staining of the cells. Cytospin
preparations of K562 cells treated with imatinib demonstrated a
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FIGURE 2. (A) Inhibition of DNA synthesis measured by 3H-thymidine incorporation
in K562, Kbcl2v and KbclX treated with 0.5 µM and 2.5 µM imatinib for 48 h and
72 h as indicated at the bottom of the graph. (B) Inhibition of DNA synthesis in
K562, Kbcl2v and KbclX treated with 0.5 mM busulfan (BU), 0.5 mM hydroxyurea
(HU) and 2000 UI/ mL of IFNa for 72 h. The data obtained with 0.5 µM imatinib is
                               included for comparison.
high fraction of apoptotic cells which were absent in the Kbcl2v and
KbclX cells (Fig. 3B), thus confirming the result observed through
the annexin V assay.
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FIGURE 3. Lack of apoptosis of Kbcl2v and KbclX cells in the presence of imatinib.
(A) Cells were treated for 2 days with 0.5 μM or 2.5 μM imatinib as indicated and
the extent of apoptosis was assessed by the binding of annexin V to cell surface
as determined by flow cytometry. (B) Cytospin preparations stained with May
Grumwald-Giemsa of the indicated cells treated with 0.5 µM or 2.5 µM imatinib
for 2 days. Note the absence of apoptotic cells in the Kbcl2v and KbclX cell lines.
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These results confirm that Bcl2 and BclX conferred complete
resistance to imatinib-mediated apoptosis. Although it has been
proposed that apoptosis induction is a major mechanism for the
cytotoxic effect of imatinib in vitro (5, 6) our results underscores the
importance of apoptosis-independent mechanisms for imatinib
antiproliferative activity. It is conceivably that non-apoptotic
mechanisms are responsible for the cytostatic effect of imatinib, and
allows the restoration of cell growth when the drug is removed. In
consistency with this result, it has been reported that imatinib
selectively suppresses CML primitive progenitors by reversing
abnormally increased proliferation but does not significantly increase
apoptosis (10).
Thus, our results suggest that the growth inhibitory effect of
imatinib is mediated two concomitant mechanisms: one cytotoxic
mechanism that triggers an apoptotic program and another cytostatic
mechanism unrelated to apoptosis. This second mechanism would
be the responsible for the growth retardation induced in cells
expressing Bcl2 and BclX. Also, the results suggest that this cytostatic
mechanism could be important for the imatinib activity in vivo.
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